Shots: Astellas partners with Concerto HealthAI to uitilize Concerto’s RWD in order to track the response in patients with FLT3 mutation-positive r/r AML The companies will utilize ASCO’s CancerLinQ […]readmore
Tags : RWE
Shots: The EMPRISE study involves assessing of Jardiance vs DPP-4 inhibitors in ~35,000 people with T2D initiated from 2014 to 2019, demonstrated 44% reduction in relative risk of hospitalization […]readmore
Shots: Real Time Evidence resulted in 9/10 responders experiencing anxiety (61%), insomnia (56%) and depression (56%), also affects their family and friends with anxiety (59%) and depression (45%). The reports […]readmore